Synonym
Pipotiazine palmitate
IUPAC/Chemical Name
Hexadecanoic acid, 2-(1-(3-(2-((dimethylamino)sulfonyl)-10H-phenothiazin-10-yl)propyl)-4-piperidinyl)ethyl ester
InChi Key
KTOYYUONFQWSMW-UHFFFAOYSA-N
InChi Code
InChI=1S/C40H63N3O4S2/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-22-40(44)47-32-27-34-25-30-42(31-26-34)28-19-29-43-36-20-17-18-21-38(36)48-39-24-23-35(33-37(39)43)49(45,46)41(2)3/h17-18,20-21,23-24,33-34H,4-16,19,22,25-32H2,1-3H3
SMILES Code
CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc4ccc(cc24)S(=O)(=O)N(C)C)CC1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
714.08
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Dinesh M, David A, Quraishi SN. Depot pipotiazine palmitate and undecylenate for schizophrenia. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001720. Review. PubMed PMID: 15495016.
2: De Schepper PJ, Vranckx C, Verbeeck R, Van den Berghe ML. Pipotiazine pharmacokinetics after p.o. and i.v. administration in man. Correlation between blood levels and effect on the handwriting area. Arzneimittelforschung. 1979;29(7):1056-62. PubMed PMID: 40577.
3: Scatton B, Boireau A, Garret C, Glowinski J, Julou L. Action of the palmitic ester of pipotiazine on dopamine metabolism in the nigro-striatal, meso-limbic and meso-cortiacal systems. Naunyn Schmiedebergs Arch Pharmacol. 1977 Jan;296(2):169-75. PubMed PMID: 13318.
4: Gallant DM, Mielke D, Bishop G, Oelsner T, Guerrero-Figueroa R. Pipotiazine palmitate: an evaluation of a new long acting intramuscular antipsychotic agent in severely ill schizophrenic patients. Dis Nerv Syst. 1975 Apr;36(4):193-6. PubMed PMID: 1090427.
5: Simpson GM, Varga V. Pipotiazine palmitate: a new depot neuroleptic. Curr Ther Res Clin Exp. 1975 Mar;17(3):276-80. PubMed PMID: 236151.
6: Smith M, de Souza MA, Pugliese S, Mari Jde J. In vivo study of the mutagenicity of biperidine, pipotiazine, chlorpromazine, and haloperidol. Am J Med Genet. 1996 Apr 9;67(2):238. PubMed PMID: 8723058.
7: Hyrman V. Pipotiazine palmitate, a long acting drug, indeed: a case report. Can J Psychiatry. 1985 Apr;30(3):221-2. PubMed PMID: 2859922.